-+ 0.00%
-+ 0.00%
-+ 0.00%

Merck Partners With Isomorphic Labs on AI-Driven Cancer Drug Discovery

PUBT·11/19/2026 11:45:54
Listen to the news
Merck Partners With Isomorphic Labs on AI-Driven Cancer Drug Discovery
  • Merck entered a research collaboration with Isomorphic Labs to discover small-molecule drug candidates against a strategically important oncology target.
  • Isomorphic Labs will use its AI drug design engine with proprietary data supplied by Merck to generate molecular designs.
  • The drugmaker will handle preclinical and clinical development, manufacturing and commercialization of products resulting from the collaboration.
  • Isomorphic Labs will receive an upfront payment, with eligibility for milestone payments and tiered royalties on net sales.
  • The agreement also gives Isomorphic Labs an option to co-fund development in exchange for higher royalties.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261119112890) on November 19, 2026, and is solely responsible for the information contained therein.